Blood harmane, blood lead, and severity of hand tremor: Evidence of additive effects

NeuroToxicology

Volumn 32, Issue 2, 2011, Pages 227-232

  Louis, Elan D ^a,b,c   Factor Litvak, Pam ^c   Gerbin, Marina ^a   Slavkovich, Vesna ^c   Graziano, Joseph H ^b,c   Jiang, Wendy ^d   Zheng, Wei ^d  

^a Vagelos College of Physicians and Surgeons   (United States)

^b Purdue University ^*  (United States)

^c Department of Medicine   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

Epidemiology; Essential tremor; Etiology; Harmane; Lead; Neurology; Toxicant; Tremor

Indexed keywords

HARMAN; LEAD;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ESSENTIAL TREMOR; FEMALE; HAND TREMOR; HUMAN; HYPOTHESIS; LEAD BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DRUG SYNERGISM; ENVIRONMENTAL EXPOSURE; ESSENTIAL TREMOR; FEMALE; HAND; HARMINE; HUMANS; LEAD; MALE; MIDDLE AGED; TREMOR; YOUNG ADULT;

EID: 79952107883     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2010.12.002     Document Type: Article

References (59)

1. Benito-Leon J., Bermejo-Pareja F., Morales J.M., Vega S., Molina J.A. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord 2003, 18:389-394.
2. Benito-Leon J., Louis E.D. Essential tremor: emerging views of a common disorder. Nat Clin Pract Neurol 2006, 2:666-678.
3. Booze R.M., Mactutus C.F., Annau Z., Tilson H.A. Neonatal triethyl lead neurotoxicity in rat pups: initial behavioral observations and quantification. Neurobehav Toxicol Teratol 1983, 5:367-375.
4. Clark L.N., Park N., Kisselev S., Rios E., Lee J.H., Louis E.D. Replication of the LINGO1 gene association with essential tremor in a North American population. Eur J Hum Genet 2010, 18:838-843.
5. Coulehan J.L., Hirsch W., Brillman J., Sanandria J., Welty T.K., Colaiaco P., et al. Gasoline sniffing and lead toxicity in Navajo adolescents. Pediatrics 1983, 71:113-117.
6. Counter S.A., Buchanan L.H., Ortega F. Gender differences in blood lead and hemoglobin levels in Andean adults with chronic lead exposure. Int J Occup Environ Health 2001, 7:113-118.
7. Dogu O., Louis E.D., Tamer L., Unal O., Yilmaz A., Kaleagasi H. Elevated blood lead concentrations in essential tremor: a case-control study in Mersin, Turkey. Environ Health Perspect 2007, 115:1564-1568.
8. Dogu O., Sevim S., Camdeviren H., Sasmaz T., Bugdayci R., Aral M., et al. Prevalence of essential tremor: door-to-door neurologic exams in Mersin Province, Turkey. Neurology 2003, 61:1804-1806.
9. Du W., Aloyo V.J., Harvey J.A. Harmaline competitively inhibits [3H]MK-801 binding to the NMDA receptor in rabbit brain. Brain Res 1997, 770:26-29.
10. Fuentes J.A., Longo V.G. An investigation on the central effects of harmine, harmaline and related beta-carbolines. Neuropharmacology 1971, 10:15-23.
11. Gearhart D.A., Collins M.A., Lee J.M., Neafsey E.J. Increased beta-carboline 9N-methyltransferase activity in the frontal cortex in Parkinson's disease. Neurobiol Dis 2000, 7:201-211.
12. Goldings A.S., Stewart R.M. Organic lead encephalopathy: behavioral change and movement disorder following gasoline inhalation. J Clin Psychiatry 1982, 43:70-72.
13. Guan Y., Louis E.D., Zheng W. Toxicokinetics of tremorogenic natural products, harmane and harmine, in male Sprague-Dawley rats. J Toxicol Environ Health A 2001, 64:645-660.
14. Gulcher J.R., Jonsson P., Kong A., Kristjansson K., Frigge M.L., Karason A., et al. Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nat Genet 1997, 17:84-87.
15. Harlan W.R. The relationship of blood lead levels to blood pressure in the U.S. population. Environ Health Perspect 1988, 78:9-13.
16. Higgins J.J., Pho L.T., Nee L.E. A gene (ETM) for essential tremor maps to chromosome 2p22-p25. Mov Disord 1997, 12:859-864.
17. Jiménez-Jiménez F.J.d.T-H.M., Alonso-Navarro H., Ayuso-Peralta L., Arévalo-Serrano J., Ballesteros-Barranco A., Puertas I., et al. Environmental risk factors for essential tremor. Eur Neurol 2007, 58:106-113.
18. Kuhn W., Muller T., Grosse H., Rommelspacher H. Plasma harman and norharman in Parkinson's disease. J Neural Transm Suppl 1995, 46:291-295.
19. Kurtin D., Therrell B.L., Patterson P. Demographic risk factors associated with elevated lead levels in Texas children covered by Medicaid. Environ Health Perspect 1997, 105:66-68.
20. Lewin L. Untersuchungen Uber Banisteria caapi Sp. Arch Exp Pathol Pharmacol 1928, 129:133-149.
21. Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968, 16:622-626.
22. Louis E.D. Etiology of essential tremor: should we be searching for environmental causes?. Mov Disord 2001, 16:822-829.
23. Louis E.D. Environmental epidemiology of essential tremor. Neuroepidemiology 2008, 31:139-149.
24. Louis E.D., Applegate L.M., Factor-Litvak P., Parides M.K., Andrews L. Essential tremor: occupational exposures to manganese and organic solvents. Neurology 2004, 63:2162-2164.
25. Louis E.D., Barnes L., Albert S.M., Cote L., Schneier F.R., Pullman S.L., et al. Correlates of functional disability in essential tremor. Mov Disord 2001, 16:914-920.
26. Louis E.D., Factor-Litvak P., Parides M., Andrews L., Santella R.M., Wolff M.S. Organochlorine pesticide exposure in essential tremor: a case-control study using biological and occupational exposure assessments. Neurotoxicology 2006, 27:579-586.
27. Louis E.D., Faust P.L., Vonsattel J.P., Honig L.S., Rajput A., Robinson C.A., et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain 2007, 130:3297-3307.
28. Louis E.D., Ferreira J.J. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 2010, 25:534-541.
29. Louis E.D., Ford B., Lee H., Andrews H. Does a screening questionnaire for essential tremor agree with the physician's examination?. Neurology 1998, 50:1351-1357.
30. Louis E.D., Ford B., Pullman S., Baron K. How normal is 'normal'? Mild tremor in a multiethnic cohort of normal subjects. Arch Neurol 1998, 55:222-227.
31. Louis E.D., Jiang W., Pellegrino K.M., Rios E., Factor-Litvak P., Henchcliffe C., et al. Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor. Neurotoxicology 2008, 29:294-300.
32. Louis E.D., Jurewicz E.C., Applegate L., Factor-Litvak P., Parides M., Andrews L., et al. Association between essential tremor and blood lead concentration. Environ Health Perspect 2003, 111:1707-1711.
33. Louis E.D., Ottman R., Ford B., Pullman S., Martinez M., Fahn S., et al. The Washington heights-inwood genetic study of essential tremor: methodologic issues in essential-tremor research. Neuroepidemiology 1997, 16:124-133.
34. Louis E.D., Thawani S.P., Andrews H.F. Prevalence of essential tremor in a multiethnic, community-based study in northern Manhattan, New York, NY. Neuroepidemiology 2009, 32:208-214.
35. Louis E.D., Zheng W., Applegate L., Shi L., Factor-Litvak P. Blood harmane concentrations and dietary protein consumption in essential tremor. Neurology 2005, 65:391-396.
36. Louis E.D., Zheng W., Jurewicz E.C., Watner D., Chen J., Factor-Litvak P., et al. Elevation of blood beta-carboline alkaloids in essential tremor. Neurology 2002, 59:1940-1944.
37. Louis E.D., Zheng W., Mao X., Shungu D.C. Blood harmane is correlated with cerebellar metabolism in essential tremor: a pilot study. Neurology 2007, 69:515-520.
38. Martin F.C., Thu Le.A., Handforth A. Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. Mov Disord 2005, 20:298-305.
39. McKenna D.J. Plant hallucinogens: springboards for psychotherapeutic drug discovery. Behav Brain Res 1996, 73:109-116.
40. Milner T.E., Cadoret G., Lessard L., Smith A.M. EMG analysis of harmaline-induced tremor in normal and three strains of mutant mice with Purkinje cell degeneration and the role of the inferior olive. J Neurophysiol 1995, 73:2568-2577.
41. Moralez L.S., Gutierrez P., Escarce J.J. Demographic and socioeconomic factors associated with blood lead levels among Mexican-American children and adolescents in the United States. Public Health Rep 2005, 120:448-454.
42. Nriagu J., Burt B., Linder L., Ismail A., Sohn W. Lead levels in blood and saliva in a low-income population of Detroit, Michigan. Int J Hyg Environ Health 2006, 209:109-121.
43. O'Hearn E., Long D.B., Molliver M.E. Ibogaine induces glial activation in parasagittal zones of the cerebellum. Neuroreport 1993, 4:299-302.
44. O'Hearn E., Molliver M.E. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 1993, 55:303-310.
45. O'Hearn E., Molliver M.E. The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity. J Neurosci 1997, 17:8828-8841.
46. Pfau W., Skog K. Exposure to beta-carbolines norharman and harman. J Chromatogr B Anal Technol Biomed Life Sci 2004, 802:115-126.
47. Robertson H.A. Harmaline-induced tremor: the benzodiazepine receptor as a site of action. Eur J Pharmacol 1980, 67:129-132.
48. Rommelspacher H., Schmidt L.G., May R. Plasma norharman (beta-carboline) levels are elevated in chronic alcoholics. Alcohol Clin Exp Res 1991, 15:553-559.
49. Salemi G., Aridon P., Calagna G., Monte M., Savettieri G. Population-based case-control study of essential tremor. Ital J Neurol Sci 1998, 19:301-305.
50. Schroeder H.A., Tipton I.H. The human body burden of lead. Arch Environ Health 1968, 17:965-978.
51. Seshia S.S., Rjani K.R., Boeckx R.L., Chow P.N. The neurological manifestations of chronic inhalation of leaded gasoline. Dev Med Child Neurol 1978, 20:323-334.
52. Shatunov A., Sambuughin N., Jankovic J., Elble R., Lee H.S., Singleton A.B., et al. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain 2006, 129:2318-2331.
53. Sinton C.M., Krosser B.I., Walton K.D., Llina R.R. The effectiveness of different isomers of octanol as blockers of harmaline-induced tremor. Pflugers Arch 1989, 414:31-36.
54. Valpey R., Sumi S.M., Copass M.K., Goble G.J. Acute and chronic progressive encephalopathy due to gasoline sniffing. Neurology 1978, 28:507-510.
55. Wakabayashi K., Totsuka Y., Fukutome K., Oguri A., Ushiyama H., Sugimura T. Human exposure to mutagenic/carcinogenic heterocyclic amines and comutagenic beta-carbolines. Mutat Res 1997, 376:253-259.
56. Willett W.C., Sampson L., Stampfer M.J., Rosner B., Bain C., Witschi J., et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985, 122:51-65.
57. Winegar D.A., Levy B.S., Andrews J.S., Landrigan P.J., Scruton W.H., Krause M.J. Chronic occupational exposure to lead: an evaluation of the health of smelter workers. J Occup Med 1977, 19:603-606.
58. Young R.S., Grzyb S.E., Crismon L. Recurrent cerebellar dysfunction as related to chronic gasoline sniffing in an adolescent girl. Lead poisoning from " leaded" gasoline as an attendent complication. Clin Pediatr (Phila) 1977, 16:706-708.
59. Zheng W., Wang S., Barnes L.F., Guan Y., Louis E.D. Determination of harmane and harmine in human blood using reversed-phased high-performance liquid chromatography and fluorescence detection. Anal Biochem 2000, 279:125-129.